CA2532330A1 - Highly selective norepinephrine reuptake inhibitors and methods of using the same - Google Patents
Highly selective norepinephrine reuptake inhibitors and methods of using the same Download PDFInfo
- Publication number
- CA2532330A1 CA2532330A1 CA002532330A CA2532330A CA2532330A1 CA 2532330 A1 CA2532330 A1 CA 2532330A1 CA 002532330 A CA002532330 A CA 002532330A CA 2532330 A CA2532330 A CA 2532330A CA 2532330 A1 CA2532330 A1 CA 2532330A1
- Authority
- CA
- Canada
- Prior art keywords
- methods
- suffering
- human
- same
- highly selective
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title abstract 3
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 5
- 208000020016 psychiatric disease Diseases 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- CBQGYUDMJHNJBX-RTBURBONSA-N reboxetine Chemical compound CCOC1=CC=CC=C1O[C@H](C=1C=CC=CC=1)[C@@H]1OCCNC1 CBQGYUDMJHNJBX-RTBURBONSA-N 0.000 abstract 2
- 229960003770 reboxetine Drugs 0.000 abstract 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 abstract 2
- 241000282412 Homo Species 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 229940076279 serotonin Drugs 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Methods and compositions for treating humans suffering from, or preventing a human from suffering, a physiological or psychiatric disease, disorder, or a condition wherein inhibiting reuptake of nonpinephrine is a benefit are disclosed. The compositions comprise a compound having a pharmacological selectivity of serotonin (K i)/nonpinephrine (K i) of at least about 5000. Examples of such compounds include reboxetine, and more preferably optically pure (S,S) enantiomer of reboxetine. The methods generally include administration of a therapeutic amount of such compositions. Also disclosed are preparations of a medicament from the composition, and uses of the composition in a manufacture of the medicament to treat a human suffering from, or preventing a human from suffering, a physiological or psychiatric disease, disorder, or condition.
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14196899P | 1999-07-01 | 1999-07-01 | |
| US60/141,968 | 1999-07-01 | ||
| US14413199P | 1999-07-16 | 1999-07-16 | |
| US60/144,131 | 1999-07-16 | ||
| US15825699P | 1999-10-06 | 1999-10-06 | |
| US60/158,256 | 1999-10-06 | ||
| US17038199P | 1999-12-13 | 1999-12-13 | |
| US60/170,381 | 1999-12-13 | ||
| CA002375908A CA2375908C (en) | 1999-07-01 | 2000-06-22 | Highly selective norepinephrine reuptake inhibitors and methods of using the same |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002375908A Division CA2375908C (en) | 1999-07-01 | 2000-06-22 | Highly selective norepinephrine reuptake inhibitors and methods of using the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2532330A1 true CA2532330A1 (en) | 2001-01-11 |
| CA2532330C CA2532330C (en) | 2009-04-21 |
Family
ID=36141768
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002532330A Expired - Fee Related CA2532330C (en) | 1999-07-01 | 2000-06-22 | Highly selective norepinephrine reuptake inhibitors and methods of using the same |
| CA002543986A Expired - Fee Related CA2543986C (en) | 1999-07-01 | 2000-06-22 | Norepinephrine reuptake inhibitors and methods of using the same |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002543986A Expired - Fee Related CA2543986C (en) | 1999-07-01 | 2000-06-22 | Norepinephrine reuptake inhibitors and methods of using the same |
Country Status (1)
| Country | Link |
|---|---|
| CA (2) | CA2532330C (en) |
-
2000
- 2000-06-22 CA CA002532330A patent/CA2532330C/en not_active Expired - Fee Related
- 2000-06-22 CA CA002543986A patent/CA2543986C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2532330C (en) | 2009-04-21 |
| CA2543986A1 (en) | 2001-01-11 |
| CA2543986C (en) | 2009-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2375908A1 (en) | Highly selective norepinephrine reuptake inhibitors and methods of using the same | |
| CA2427227A1 (en) | Lactam compound | |
| WO2002042462A3 (en) | Therapeutic agents and methods of use thereof for treating an amyloidogenic disease | |
| RU94045155A (en) | Methods of alzheimer's disease inhibition | |
| AU2005202257C1 (en) | Azacyclic compounds for use in the treatment of serotonin related diseases | |
| EA200000468A1 (en) | THERAPEUTIC COMPOSITION FOR THE ADMINISTRATION OF TOLTERODINE WITH CONTROLLED DELIVERY | |
| WO2001009118A3 (en) | Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement | |
| MY131810A (en) | Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes | |
| BR0214967A (en) | Compound, pharmaceutically acceptable salt, process for preparing a compound, pharmaceutical composition, use of a compound and method of treating a patient disorder | |
| WO2000064441A3 (en) | Compound for use as a medicament for treatment of disorders involving bronchocontraction | |
| WO2003048164A3 (en) | Adenosine a2a receptor antagonists | |
| CA2283255A1 (en) | Use of r-nsaid's for the prevention of alzheimer's disease | |
| BG104179A (en) | Phanquinon administration for the treatment of the alzheimer's disease | |
| WO1999045909A3 (en) | Use of nitrone compounds for the inhibition of angiogenesis | |
| CA2340734A1 (en) | Optically active pyridyl-4h-1,2,4-oxadiazine derivative and its use in the treatment of vascular diseases | |
| WO2002005801A3 (en) | Compositions containing diacyltartaric salts of (e)-metanicotine | |
| BG103512A (en) | Substituted pyramidine compounds and their application | |
| EP1632235A3 (en) | Use of highly selective norepinephrine reuptake inhibitors for the treatment of mental disorders | |
| WO2000076500A8 (en) | Compound for use as a medicament for treatment of disorders involving bronchocontraction | |
| MX9805317A (en) | Preventives/remedies for complications of diabetes. | |
| WO2000004012A8 (en) | COMPOUNDS SPECIFIC FOR THE HUMAN α1d ADRENERGIC RECEPTOR AND USES THEREOF | |
| CA2532330A1 (en) | Highly selective norepinephrine reuptake inhibitors and methods of using the same | |
| AU6053496A (en) | The use of sertraline to treat post myocardial infarction patients | |
| IL164317A0 (en) | Statin therapy for enhancing cognitive maintenance | |
| MA26796A1 (en) | AMINOTETRALIN DERIVATIVE FOR THERAPY OF CARDIOVASCULAR DISEASES. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |